Business Monitor InternationalPharmaceuticals & Healthcare ReportsCroatia Pharmaceuticals & Healthcare ReportPublished: 10 Nov 2011 QuarterlyReport Downloads
Price: $995.00 You save $180.00 (15%) on the regular rate Order and Enquiries
Related ProductsCroatia ProductsMultinational Companies in Croatia CD-ROMThe Croatia database features 1190 fully researched, senior executive contacts and top decision makers at 340 multinational companies in Croatia, across 34 industry sectors. Read MorePharmaceuticals & Healthcare ProductsBelgium Pharmaceuticals & Healthcare ReportThe Belgium Pharmaceuticals & Healthcare Report has been researched at source and features the latest available data and forecasts to end-2012, covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade. Read MoreReport DescriptionThe Croatia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts to end-2016 for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments. BMI's Croatia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Croatian pharmaceutical and healthcare industry. Key Benefits
CoverageDownload Table of Contents Executive Summary & Industry SWOTAn at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate. Market SummarySnapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape. Regulatory RegimeDetails of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation, advertising, as well as an analysis of the overall regulatory burden. Industry DevelopmentsFocus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues. BMI Industry Forecast To End-2016Forecasts to end-2016 for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including: Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population) Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$) Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.) Generic drug market: Generic product sales (US$bn), generic sales (% of total sales) OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.) Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market) Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt. Competitive LandscapeThe competitive landscape section provides comparative company analyses and rankings by US$ sales, % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors. Company ProfilesExamines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects. Read about our other Pharmaceuticals & Healthcare Reports
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Senator House, 85 Queen Victoria Road, London, EC4V 4AB
|